NYC-based Grow Therapy, which offers tools for mental health providers to set up virtual practices, raised a $75M Series B, bringing its total funding to $90M
Jessica Hagen / MobiHealthNews :
Context & Ripple Effects
At its October 2022 Series B, Grow Therapy was a $90M-funded bet on the supply side of teletherapy: rather than building a consumer brand like Talkspace's text-and-video counseling app, it sells matching and EHR tooling that lets independent therapists run their own virtual practices and bill insurance.
The bet compounded fast — an $88M Series C led by Sequoia in April 2024 expanded the patient-provider matching and EHR stack, and by March 2026 the company had closed a $150M Series D at a $3B valuation with more than $1B in annual revenue, making this early raise the inflection point where it outgrew the consumer-teletherapy playbook.
First-order effects
- The $75M gives Grow Therapy runway to scale the practice-management stack — matching, EHR, insurance billing — that lets solo therapists operate virtually without joining a W-2 telehealth employer.
Second-order effects
- Headway, which raised a $26M Series A in 2020 to match patients with insurance-accepting therapists, now competes with Grow on the same payer-side problem, pushing both toward deeper EHR and billing integration to lock in providers.
Third-order effects
- If the pattern holds, behavioral health consolidates around provider-enablement platforms that own scheduling, records, and reimbursement rails — leaving consumer-facing apps like Talkspace as demand channels riding on someone else's infrastructure.
The trend: Mental health funding is shifting from consumer teletherapy brands toward infrastructure that turns independent therapists into insured virtual practices.